[go: up one dir, main page]

WO2012024583A3 - Composés oxystérol - Google Patents

Composés oxystérol Download PDF

Info

Publication number
WO2012024583A3
WO2012024583A3 PCT/US2011/048416 US2011048416W WO2012024583A3 WO 2012024583 A3 WO2012024583 A3 WO 2012024583A3 US 2011048416 W US2011048416 W US 2011048416W WO 2012024583 A3 WO2012024583 A3 WO 2012024583A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
disclosed
disorders
oxysterol compounds
oxysterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/048416
Other languages
English (en)
Other versions
WO2012024583A2 (fr
Inventor
Matt Epperson
Francine Farouz
Frank Stappenbeck
Wei Xiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fate Therapeutics Inc
Original Assignee
Fate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fate Therapeutics Inc filed Critical Fate Therapeutics Inc
Publication of WO2012024583A2 publication Critical patent/WO2012024583A2/fr
Publication of WO2012024583A3 publication Critical patent/WO2012024583A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne des composés destinés à être utilisés dans le traitement de troubles osseux, de l'obésité, de troubles cardiovasculaires et de troubles neurologiques. Les composés ont la structure suivante (I) : (I) comprenant les stéréoisomères, les sels pharmaceutiquement acceptables et les promédicaments de ceux-ci, dans laquelle X, Y et R1 sont tels que définis ici. L'invention concerne également des procédés associés à la préparation et à l'utilisation de tels composés, ainsi que des compositions pharmaceutiques comprenant de tels composés.
PCT/US2011/048416 2010-08-20 2011-08-19 Composés oxystérol Ceased WO2012024583A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37549010P 2010-08-20 2010-08-20
US61/375,490 2010-08-20

Publications (2)

Publication Number Publication Date
WO2012024583A2 WO2012024583A2 (fr) 2012-02-23
WO2012024583A3 true WO2012024583A3 (fr) 2012-04-12

Family

ID=44533205

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/048416 Ceased WO2012024583A2 (fr) 2010-08-20 2011-08-19 Composés oxystérol

Country Status (1)

Country Link
WO (1) WO2012024583A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005020928A2 (fr) 2003-08-29 2005-03-10 The Regents Of The University Of California Agents et procedes permettant d'ameliorer la formation osseuse a l'aide d'oxysterols combines a des proteines morphogeniques osseuses
CA2643732C (fr) 2006-02-27 2012-08-21 The Regents Of The University Of California Composes oxysterols et voie
EP2231164A1 (fr) 2007-12-03 2010-09-29 The Regents of the University of California Oxystérols pour l'activation du signal hedgehog, de l'ostéoinduction, de l'anti-adipogenèse et du signal wnt
CA2872734A1 (fr) * 2012-05-07 2013-11-14 The Regents Of The University Of California Nouvel analogue de l'oxysterol, l'oxy149, pour l'osteo-induction, la signalisation hedgehog et l'inhibition de l'adipogenese
JP6262723B2 (ja) * 2012-05-07 2018-01-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ オキシステロールアナログｏｘｙ１３３は、骨発生及びヘッジホッグシグナル伝達を誘導し、脂肪生成を阻害する
US9683009B2 (en) 2013-05-02 2017-06-20 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
KR20190104359A (ko) 2016-12-30 2019-09-09 프리퀀시 테라퓨틱스, 인크. 줄기/전구체 지지 세포의 자가 재생을 유도하기 위한 1h-피롤-2,5-다이온 화합물 및 이의 사용 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009073186A1 (fr) * 2007-12-03 2009-06-11 The Regents Of The University Of California Oxystérols pour l'activation du signal hedgehog, de l'ostéoinduction, de l'anti-adipogenèse et du signal wnt

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009073186A1 (fr) * 2007-12-03 2009-06-11 The Regents Of The University Of California Oxystérols pour l'activation du signal hedgehog, de l'ostéoinduction, de l'anti-adipogenèse et du signal wnt

Also Published As

Publication number Publication date
WO2012024583A2 (fr) 2012-02-23

Similar Documents

Publication Publication Date Title
WO2012024584A3 (fr) Composés oxystérol
WO2012024581A3 (fr) Composés oxystérol
WO2012016186A8 (fr) Inhibiteurs de kinases macrocycliques et leurs utilisations
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
IN2014DN09805A (fr)
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
IN2012DN03182A (fr)
IN2014DN09804A (fr)
WO2011044506A3 (fr) Composés sulfonés et leurs procédés de fabrication et d'utilisation
MX2011012122A (es) Derivados de tiofeno.
IL217378A (en) History of oxazin, containing pharmaceuticals and their use in the preparation of drugs for the treatment of neurological disorders
EP4538227A3 (fr) Compositions pharmaceutiques contenant du thiosulfate de sodium
WO2011044501A3 (fr) Analogues d'aminoglycoside antibactériens
WO2011127333A3 (fr) Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques
WO2012024583A3 (fr) Composés oxystérol
WO2012021715A3 (fr) Formulations stables de linaclotide
WO2010092090A3 (fr) Nouveaux sels de la sitagliptine
WO2014045162A8 (fr) Composés d'hexahydropyrano[3,4-d][1,3]thiazine-2-amine alkyl-substitués
WO2012048129A3 (fr) Inhibiteurs de kinase de type polo
WO2008097924A3 (fr) Compositions pharmaceutiques comprenant des analogues du dextrométhorphane pour le traitement de troubles neurologiques
HK1202448A1 (en) Topical formulation for administering a compound
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.
WO2010132757A3 (fr) Analogues d'aminoglycoside antibactériens
WO2011017502A3 (fr) Formulations comprenant du linaclotide
WO2012071369A3 (fr) Antagoniste rbp4 non rétinoïde pour le traitement de la dégénérescence maculaire liée à l'âge et de la maladie de stargardt

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11749674

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11749674

Country of ref document: EP

Kind code of ref document: A2